HAS2 Inhibitors

Common HAS2 Inhibitors include, but are not limited to 4-Methylumbelliferone CAS 90-33-5, Genistein CAS 446-72-0, Emodin CAS 518-82-1, Manumycin A CAS 52665-74-4 and (-)-Epigallocatechin Gallate CAS 989-51-5.

HAS2, or Hyaluronan Synthase 2, is one of the enzymes responsible for the synthesis of hyaluronan, a major component of the extracellular matrix. Hyaluronan is a glycosaminoglycan that plays essential roles in various physiological processes, including tissue hydration, cell migration, and proliferation. It forms a critical part of the extracellular matrix in many tissues, providing structural integrity and serving as a lubricant in joint cavities. The synthesis of hyaluronan by HAS2 is vital for these functions. HAS2 is distinguished from other hyaluronan synthases (HAS1 and HAS3) by its unique ability to produce high molecular weight hyaluronan, which has specific biological activities distinct from those of lower molecular weight hyaluronans.

HAS2 inhibitors comprise a category of molecules specifically designed to hinder the activity of the HAS2 enzyme. By targeting HAS2, these inhibitors can modulate the synthesis of hyaluronan, thereby influencing the structure and function of the extracellular matrix in various tissues. The action mechanism of these inhibitors may involve direct binding to the HAS2 enzyme, blocking its active site, or disrupting its interaction with substrate molecules. By understanding the functionality and molecular interactions of HAS2 inhibitors, researchers can delve deeper into the intricate processes governing hyaluronan synthesis and its broader roles in tissue physiology. The study and development of these inhibitors can shed light on the detailed pathways involved in extracellular matrix formation and the consequences of modulating hyaluronan levels in the body.